Bristol Myers (BMY) plans to acquire Karuna Therapeutics (KRTX) for $14B, or $330 a share in cash, The Wall Street Journal’s Jonathan D. Rockoff reports. The deal would help Bristol establish a beachhead in neuroscience drugs, including a schizophrenia treatment up for approval, according to the report. “We are in the process of writing a new chapter for Bristol Myers Squibb,” Bristol CEO Christopher Boerner said in an interview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- Mirati Therapeutics downgraded to Neutral from Buy at Citi
- Bristol Myers says Phase 3 RELATIVITY-123 trial to be discontinued
- Bristol Myers, Terray Therapeutics announce multi-target collaboration
- Purple Biotech completes patient enrollment in Phase 2 pancreatic cancer trial
- The biopharma stocks to own in 2024, according to Morgan Stanley